{"filing":{"accession_number":"0001193125-26-239277","cik":"0001426800","ticker":"ASMB","company_name":"ASSEMBLY BIOSCIENCES, INC.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"asmb-20260521.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526239277/asmb-20260521.htm"},"events":[{"id":9029,"run_id":7926,"accession_number":"0001193125-26-239277","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Assembly Biosciences completed a registered public offering of 3,358,602 shares of common stock at $26.50 per share, plus pre-funded warrants to purchase 415,000 additional shares, raising approximately $107.4 million in net proceeds. Underwriters exercised their 30-day option to purchase 566,040 additional shares in full, further diluting existing shareholders.","company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1508,"accession_number":"0001193125-26-239277","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Assembly Biosciences entered into an underwriting agreement for a registered public offering of 3,358,602 shares of common stock at $26.50 per share, plus pre-funded warrants to purchase 415,000 additional shares, with net proceeds of approximately $107.4 million. The company also granted underwriters a 30-day option to purchase 566,040 additional shares, which was exercised in full. This is a material dilutive equity issuance that increases the share count and raises capital through a registered offering.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:11:47.131092+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1509,"accession_number":"0001193125-26-239277","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses pricing and closing of an \"Offering\" via press releases on May 22 and May 26, 2026. While the Item 8.01 section does not explicitly detail the offering terms, the dual announcements of pricing and closing are characteristic of a capital raise. Given Assembly Biosciences' profile as a biotech company and the formal disclosure structure, this most likely represents a dilutive equity issuance (private placement, PIPE, or public offering). The materiality is high for a biotech issuer raising capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:11:47.131092+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1508,"accession_number":"0001193125-26-239277","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Assembly Biosciences entered into an underwriting agreement for a registered public offering of 3,358,602 shares of common stock at $26.50 per share, plus pre-funded warrants to purchase 415,000 additional shares, with net proceeds of approximately $107.4 million. The company also granted underwriters a 30-day option to purchase 566,040 additional shares, which was exercised in full. This is a material dilutive equity issuance that increases the share count and raises capital through a registered offering.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:11:47.131092+00:00","company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","filing_date":"2026-05-26"},{"id":1509,"accession_number":"0001193125-26-239277","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses pricing and closing of an \"Offering\" via press releases on May 22 and May 26, 2026. While the Item 8.01 section does not explicitly detail the offering terms, the dual announcements of pricing and closing are characteristic of a capital raise. Given Assembly Biosciences' profile as a biotech company and the formal disclosure structure, this most likely represents a dilutive equity issuance (private placement, PIPE, or public offering). The materiality is high for a biotech issuer raising capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:11:47.131092+00:00","company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","filing_date":"2026-05-26"}]}